ACTINIUM PHARMAC. DL-001(7AY1) News

Date	Title
Mar 12	Actinium Pharmaceuticals to Participate at the 37th Annual Roth Conference
Mar 11	Actinium Pharmaceuticals Announces Initiation of Actimab-A Triplet Combination Frontline Trial Under NCI CRADA with Venetoclax and Taiho Oncology's Hypomethylating Agent ASTX-727 in Patients with Newly Diagnosed AML